Cancer Chemotherapy Update B. Initiate at an infusion rate of 0.875 mg/m 2 /h for 30 minutes. The infusion rate can be gradually increased as tolerated to a maximum rate of 1.75 mg/m 2 /h. C. Hydration with NS and premedication with an antihistamine, antipyretic, and opioid analgesic is recommended. D. For mild to moderate adverse reactions, the infusion rate should be reduced by 50%, and the patient monitored closely. If symptoms resolve, the infusion rate can be gradually increased to a maximum rate of 1.75 mg/m 2 /h. E. For prolonged or severe adverse reactions, the infusion should be stopped. If symptoms resolve, the infusion may be resumed at 50% of the previous rate and the patient monitored closely. F. If a prolonged or severe adverse reaction recurs, the dinutuximab infusion should be discontinued until the following day. G. If symptoms resolve and continued treatment is warranted, hydrocortisone 1 mg/kg (maximum dose 50 mg) IV should be added to the premedication regimen, and the drug should be administered at 0.875 mg/m 2 /h in an intensive care unit. H. If a prolonged or severe adverse reaction continues or recurs, permanently discontinue dinutuximab.
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%.
(All toxicities reported below are grade 3 or 4.) A. Cardiovascular: Hypotension (3% to 18%) 10,11 ; low diastolic blood pressure (3% to 15%) 12 ; low systolic blood pressure (16%). 12 B. Central Nervous System: CNS cortical symptoms (3% to 10%), 10,12 seizure (1%). 12 C. Constitutional: Acute capillary leak syndrome (1% to 23%), [10] [11] [12] decreased performance status (5%), 12 fever without infection (13% to 20%), 12 fever without neutropenia (39%). 10 D. Dermatologic: Urticaria (13%). 10 E. Endocrine/Metabolic: Hypercalcemia (5%), 10 hypokalelmia (3% to 35%), 10,12 hyponatremia (23%). 10 Note: IV = intravenous. a Conforms to dosing information listed in the manufacturer's labeling.
Cancer Chemotherapy Update F. Gastrointestinal: Diarrhea (2% to 13), 10, 12 nausea (3% to 21%), 10, 12 vomiting (6%). 10 G. Hematologic: Anemia (13% to 25), 12 leukopenia (2% to 25%), 12 lymphopenia (5% to 25%), 12 neutropenia (14% to 30%), 12 prolonged partial thromboplastin time (PTT) (5% to 6%), 12 thrombocytopenia (19% to 35%). 12 H. Hepatic: Elevated alanine transaminase (ALT) (2% to 23%), 10,12 elevated aspartate aminotransferase (AST) (2% to 10), 10,12 elevated alkaline phosphatase (5%), 12 elevated bilirubin (10%). 12 I. Hypersensitivity: Hypersensitivity reaction (2% to 25%). 10,11 J. Infection: Catheter-related infection (13%), 10 infection (3% to 39%). 10,12 K. Pain: Neuropathic (13% to 87%). [10] [11] [12] L. Pulmonary: Hypoxia (5% to 13). 10 
MECHANISM OF ACTION
Panobinostat is a pan-deacetylase inhibitor with activity against histone deacetylase (HDAC) I, II, and IV enzymes. 16 Panobinostat inhibits enzymatic activity of HDACs resulting in increased acetylation of histone proteins. 17 Accumulation of acetylated histones results in relaxing of chromatin, leading to transcriptional activation and cell cycle arrest and/or apoptosis. 17
PHARMACOKINETICS
Oral panobinostat is 21.4% bioavailable. 17, 18 The time to maximum concentration (T max ) is within 2 hours of oral administration. 17 Following ingestion after a high-fat meal, the C max and area under the time versus concentration curve (AUC) were 44% and 16% lower, respectively, compared to fasting. 17 Panobinostat is highly (90%) bound to plasma protein and is a P-glycoprotein substrate. 17 Panobinostat is extensively metabolized via reduction, hydrolysis, oxidation, and glucuronidation. 16, 17 Name:
Panobinostat
Following a single oral dose of [ 14 C] panobinostat, 29% to 51% of administered radioactivity is excreted in the urine and 44% to 77% in the feces. 19 Median clearance of panobinostat is L/h; interindividual variability in clearance is 65% to 74%. 14, 15 Terminal T 1/2 is 30 to 37 hours. 16, 19 AUC decreases from 104 to 88 µg•h/mL as BSA increases from 1.8 to 2.1 m 2 . 18 AUC decreases from 102 to 95 µg•h/mL as age increases from 51 to 70 years. 15 In patients with mild, moderate, and severe renal failure, panobinostat AUC 0-inf is 64%, 99%, and 59% of the non-impaired group. 20 AUC 0-inf is increased 43% and 105% in patients with mild and moderate hepatic failure compared with normal patients. 17 Selected therapeutic regimens of panobinostat are shown in Table 2 .
PREPARATION
A. Follow institutional policies for preparation of hazardous medications when dispensing panobinostat. B. Panobinostat is available as 10 mg, 15 mg, and 20 mg capsules. C. The manufacturer recommends the capsules not be opened, crushed, or chewed. 17
STABILITY
A. Panobinostat should be stored at 20°C to 25°C (68°F-77°F). B. Brief (less than 24 hours) exposure to temperatures up to 30°C (86°F) is acceptable.
ADMINISTRATION
A. Panobinostat should be taken by mouth once a day. B. Panobinostat can be taken with or without food. C. If a dose is missed, it can be taken up to 12 hours after the scheduled dose time.
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities; but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%.
A. Cardiovascular: Hypotension (all grades) 14%
to 20%, 21, 22 (grade 3) 2% to 5%, 21, 22 (grade 4) 1% to 4%. 21 21 ; anorexia (all grades) 28% to 45%, [21] [22] [23] (grade 3) 3%, 21 (grade 3 or 4) 2% 23 ; constipation (all grades) 27% to 29% 21, 23 ; diarrhea (all grades) 68% to 73%, [21] [22] [23] (grade 3) 18% to 24%, [21] [22] [23] (grade 4) 1% to 2% [21] [22] [23] ; dyspepsia (all grades) 12%, 21 (grade 3) 1% 21 ; flatulence (all grades) 11%, 22 (grade 3) 5% 22 ; nausea (all grades) 36% to 61%, [21] [22] [23] (grade 3) 5% to 11% 21, 22 ; vomiting (all grades), 21, 22 (grade 3) 7%, 21 (grade 3 or 4) 5%. 23 F. Hematologic: Anemia (all grades) 18% to 62%, [21] [22] [23] (grade 3) 9% to 15%, 21, 22 (grade 3 or 4) 18% 23 ; lymphopenia (all grades) 83%, 21 (grade 3) 42%, 21 (grade 4) 12% 21 ; thrombocytopenia (all grades) 65% to 98%, [21] [22] [23] (grade 3) 13% to 33%, 21, 22 (grade 4) 35% to 51%, 21, 22 (grade 3 or 4) 81%. 23 Conforms to dosing information listed in the manufacturer's labeling.
